Marevan

Warfarin Sodium, the active ingredient in Marevan, is an anticoagulant presented as an oral formulation for oral use. It is employed to prevent and treat clot‑related conditions such as venous thromboembolism, stroke in atrial fibrillation, and thromboembolic events in patients with prosthetic heart valves.

GNH USA supplies Marevan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Marevan is an oral anticoagulant used to manage conditions where abnormal clot formation poses a risk.

- Venous thromboembolism: prevents new clot formation and treats existing clots. - Atrial fibrillation: reduces the risk of stroke by inhibiting clot development. - Prosthetic heart valves: provides prophylaxis against thromboembolic events associated with artificial valves.

Marevan may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Bruising or minor bleeding - Gastrointestinal upset (nausea, abdominal discomfort) - Headache - Dizziness or light‑headedness - Skin rash or itching - Minor hematuria

Serious or Rare Side Effects: - Severe or uncontrolled bleeding - Hemorrhagic stroke - Skin necrosis - Anaphylactic or severe allergic reaction - Significant liver enzyme elevation

Before prescribing Marevan, clinicians should consider several safety measures.

- Monitor INR regularly: adjust dosage to maintain therapeutic range. - Assess bleeding risk: review history of ulcers, surgery, or trauma. - Avoid strong CYP2C9 inhibitors: these may increase warfarin plasma levels. - Educate patients on signs of bleeding: bruising, blood in urine or stool, prolonged nosebleeds. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Marevan interacts with many medicines; some require avoidance while others need close monitoring.

Major Interactions (Avoid): - Amiodarone: can markedly increase anticoagulant effect. - Azole antifungals (e.g., fluconazole): raise warfarin plasma concentrations. - Rifampin: reduces warfarin effectiveness.

Moderate Interactions (Monitor Closely): - NSAIDs: elevate risk of gastrointestinal bleeding. - Aspirin: additive antiplatelet effect may increase bleeding. - Vitamin K‑rich foods: may diminish anticoagulant response.